Display options
Cite
Deibert P, Xander C, Blum HE, et al. Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Core Evid. 2010;4:247-58doi: 10.2147/ce.s8556.
Deibert, P., Xander, C., Blum, H. E., & Becker, G. (2010). Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Core evidence, 4247-58. https://doi.org/10.2147/ce.s8556
Deibert, Peter, et al. "Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation." Core evidence vol. 4 (2010): 247-58. doi: https://doi.org/10.2147/ce.s8556
Deibert P, Xander C, Blum HE, Becker G. Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Core Evid. 2010 Jun 15;4:247-58. doi: 10.2147/ce.s8556. PMID: 20694079; PMCID: PMC2899781.
Copy Download .nbib Format: NLM
Share it on

Core Evid. 2010 Jun 15;4:247-58. doi: 10.2147/ce.s8556.

Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation.

Core evidence

Peter Deibert, Carola Xander, Hubert E Blum, Gerhild Becker

Affiliations

  1. Department of Rehabilitative and Preventive Sports Medicine.

PMID: 20694079 PMCID: PMC2899781 DOI: 10.2147/ce.s8556

Abstract

INTRODUCTION: Constipation is a distressing side effect of opioid treatment, being so irksome in some cases that patients would rather suffer the pain than the side effect of opioid analgesics. Stool softeners or stimulating laxatives are often ineffective or even aggravate the situation. A new efficacious and safe drug is needed to limit the frequently observed side effects induced by effective opioid-based analgesic therapy and to improve the quality of life for patients, most of whom are impaired by a severe disease.

AIMS: The purpose of this article is to assess current evidence supporting the use of the peripherally acting mu-opioid receptor antagonist, methylnaltrexone, to restrict passage across the blood-brain barrier in patients with opioid-induced bowel dysfunction.

EVIDENCE REVIEW: There are now convincing data from phase II and multicenter phase III randomized, double-blind, placebo-controlled trials that methylnaltrexone induces laxation in patients with long-term opioid use without affecting central analgesia or precipitation of opioid withdrawal. Onset of the effect is rapid and improvement is maintained for at least 3 months during the drug treatment. The action of methylnaltrexone is dose dependent. Weight-related dosing appeared to be effective. There were no severe side effects or signs of opioid withdrawal. Adverse events, most frequently abdominal cramping or nausea, were usually mild to moderate. Methylnaltrexone is contraindicated in patients with known or suspected mechanical intestinal stenosis. Patients receiving methylnaltrexone must be monitored.

PLACE IN THERAPY: Methylnaltrexone applied subcutaneously every other day may be given to patients suffering from chronic constipation due to opioid therapy for whom laxatives do not provide adequate relief of their symptoms.

Keywords: chronic severe pain; constipation; methylnaltrexone; opioid analgesics; opioid-induced bowel dysfunction

References

  1. JAMA. 2000 Jan 19;283(3):367-72 - PubMed
  2. Mayo Clin Proc. 2008 Oct;83(10):1116-30 - PubMed
  3. Clin Pharmacol Ther. 1996 Apr;59(4):469-75 - PubMed
  4. Eur J Clin Pharmacol. 1988;34(4):343-52 - PubMed
  5. J Pain Symptom Manage. 2007 Nov;34(5):547-65 - PubMed
  6. Am J Hosp Palliat Care. 2005 Sep-Oct;22(5):375-81 - PubMed
  7. Ann N Y Acad Sci. 2008 Sep;1138:278-98 - PubMed
  8. J Pain. 2003 Jun;4(5):231-56 - PubMed
  9. J Clin Pharmacol. 1997 Jan;37(1):25-30 - PubMed
  10. Palliat Med. 1996 Apr;10(2):135-44 - PubMed
  11. J Clin Oncol. 2001 May 1;19(9):2542-54 - PubMed
  12. Drug Saf. 1994 Jan;10(1):47-65 - PubMed
  13. Clin Pharmacol Ther. 2000 Apr;67(4):398-404 - PubMed
  14. Drugs. 2003;63(7):649-71 - PubMed
  15. Am J Hosp Palliat Care. 2008 Aug-Sep;25(4):282-4 - PubMed
  16. Anesth Analg. 2008 Dec;107(6):1965-7 - PubMed
  17. Adv Exp Med Biol. 1998;437:13-9 - PubMed
  18. Drug Alcohol Depend. 1998 Oct 1;52(2):161-5 - PubMed
  19. Core Evid. 2008 Jun;3(1):45-54 - PubMed
  20. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003448 - PubMed
  21. N Engl J Med. 2008 May 29;358(22):2332-43 - PubMed
  22. J Pain Symptom Manage. 1999 Oct;18(4):303-9 - PubMed
  23. Neuropharmacology. 1999 Mar;38(3):425-32 - PubMed
  24. Anesth Analg. 1994 Apr;78(4):701-5 - PubMed
  25. J Pain Symptom Manage. 1997 May;13(5):254-61 - PubMed
  26. J Support Oncol. 2009 Jan-Feb;7(1):39-46 - PubMed
  27. J Clin Oncol. 1998 Apr;16(4):1588-93 - PubMed
  28. Anaesthesia. 1980 Jan;35(1):17-21 - PubMed
  29. BMJ. 2005 Oct 8;331(7520):825-9 - PubMed
  30. Gastroenterology. 2000 Feb;118(2):316-27 - PubMed
  31. Clin Pharmacol Ther. 1997 Apr;61(4):467-75 - PubMed
  32. J Pharmacol Exp Ther. 2002 Jan;300(1):118-23 - PubMed
  33. Aliment Pharmacol Ther. 2008 Aug 1;28(3):312-25 - PubMed
  34. Dig Dis Sci. 2002 Oct;47(10):2222-30 - PubMed
  35. BMJ. 2001 May 12;322(7295):1154-8 - PubMed
  36. Acta Anaesthesiol Belg. 1995;46(3-4):127-32 - PubMed
  37. Palliat Med. 1998 Sep;12(5):375-82 - PubMed
  38. J Pain Symptom Manage. 1998 Oct;16(4):240-4 - PubMed
  39. Pain. 1996 Mar;64(3):527-534 - PubMed
  40. Palliat Med. 2006 Jun;20(4):419-23 - PubMed
  41. Palliat Med. 2000 Mar;14(2):111-9 - PubMed
  42. Neuropeptides. 1998 Jun;32(3):287-91 - PubMed
  43. J Pain Symptom Manage. 2008 May;35(5):458-68 - PubMed
  44. Clin Pharmacol Ther. 2007 Jul;82(1):48-53 - PubMed
  45. J Pain Symptom Manage. 2002 Jul;24(1):71-90 - PubMed
  46. Am J Gastroenterol. 2005 Jan;100(1):232-42 - PubMed
  47. Anesth Analg (Paris). 1976 Sep-Oct;33(5):757-62 - PubMed
  48. Am J Surg. 2001 Nov;182(5A Suppl):11S-18S - PubMed
  49. Curr Opin Investig Drugs. 2008 Jan;9(1):90-100 - PubMed
  50. J Pain Symptom Manage. 1992 Jul;7(5):259-66 - PubMed
  51. Expert Opin Investig Drugs. 2007 Feb;16(2):181-94 - PubMed
  52. Anesthesiology. 1997 Oct;87(4):765-70 - PubMed
  53. Lancet. 2009 Apr 4;373(9670):1198-206 - PubMed
  54. J Pain Symptom Manage. 2002 Aug;24(2):91-6 - PubMed
  55. Neurogastroenterol Motil. 2005 Apr;17(2):157-65 - PubMed
  56. Pain. 1999 Dec;83(3):631-635 - PubMed
  57. Am J Gastroenterol. 2007 Jul;102(7):1436-41 - PubMed
  58. Int J Clin Pract. 2007 Jul;61(7):1181-7 - PubMed
  59. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006332 - PubMed
  60. J Clin Pharmacol. 2005 May;45(5):538-46 - PubMed
  61. JAMA. 2000 Sep 20;284(11):1383-4 - PubMed
  62. J Clin Pharmacol. 1998 Nov;38(11):1017-20 - PubMed
  63. Ann Emerg Med. 1983 Jul;12(7):438-45 - PubMed
  64. J Clin Oncol. 2000 Apr;18(8):1780-99 - PubMed
  65. Pharmacol Ther. 2008 Jan;117(1):162-87 - PubMed
  66. Life Sci. 2001 May 4;68(24):2675-84 - PubMed
  67. Expert Opin Investig Drugs. 2006 May;15(5):541-52 - PubMed

Publication Types